Irbesartan Stada

Irbesartan, the active ingredient in Irbesartan Stada, is an Angiotensin II receptor blocker presented as an oral tablet for oral use. It is employed to manage high blood pressure and to protect kidney function in patients with diabetic nephropathy. The medication works by selectively blocking AT1 receptors, reducing vasoconstriction and aldosterone-mediated fluid retention.

GNH USA supplies Irbesartan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to lower blood pressure and protect renal function. - Hypertension: lowers blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney disease in patients with type 2 diabetes. - Essential hypertension: provides long‑term blood pressure control.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Fatigue: feeling of tiredness or lack of energy. - Nausea: occasional upset stomach. - Upper respiratory infection: mild cold‑like symptoms. - Hyperkalemia: elevated potassium levels, usually mild.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure causing faintness or shock. - Acute renal failure: sudden loss of kidney function, especially in patients with pre‑existing renal disease. - Hepatic injury: abnormal liver enzymes or hepatitis. - Life‑threatening hyperkalemia: dangerously high potassium levels. - Anaphylactic reaction: rare but severe allergic response.

Irbesartan should be used with careful monitoring and consideration of patient‑specific factors. - Monitor blood pressure: check regularly to ensure therapeutic effect. - Assess renal function: evaluate serum creatinine and eGFR before and during treatment. - Check electrolytes: especially potassium levels to avoid hyperkalemia. - Avoid in severe hepatic impairment: consider alternative therapy. - Pregnancy: contraindicated in the second and third trimesters due to fetal risk. - Store at ambient temperature: keep in the original pack, protect from moisture.

Irbesartan may interact with several medicines, requiring attention to avoid adverse outcomes. Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Potassium‑sparing diuretics or supplements: heightened risk of hyperkalemia. - ACE inhibitors: additive potassium increase and potential hypotension. Moderate Interactions (Monitor Closely): - NSAIDs: may diminish antihypertensive effect and affect renal function. - Lithium: possible increase in lithium serum concentrations. - Thiazide diuretics: may require dose adjustment of either agent.